Oracle Health Sciences InForm electronic data capture platform utilizes Proteus solution, enabling greater accuracy in measuring medication adherence during clinical trials.
Highly engaged patients that consistently take their prescribed medications as directed are the cornerstone of a successful clinical trial. Researchers have long struggled to effectively and efficiently validate adherence-relying on an arduous and often inaccurate combination of self-reporting and lab tests. To help health sciences organizations more effectively track and manage the use of medication during clinical trials, Oracle has introduced Oracle Health Sciences InForm Medication Adherence Insights Cloud Service.
This solution not only enables clinical trial sponsors to automatically capture precise and timely data about medication adherence, it can also help accelerate insight about drug efficacy and safety and speed clinical trials, which can, in turn, increase trial success rates.
News Facts
“Oracle Health Sciences InForm Medication Adherence Insights Cloud Service helps health sciences organizations effectively address two long-standing and complex challenges: measuring participant adherence to drug protocols and identifying the optimum dosing regimen for recommended use,” said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences. “This groundbreaking solution-the direct result of a collaboration between Oracle and Proteus Digital Health-is a powerful example of how we can rapidly combine our industry-leading clinical trial data capture and management solutions with emerging technologies, such as digital pills, to help health sciences organizations transform the drug development and approval process.”
“The medication adherence option uniquely addresses the most critical information in a clinical trial: ‘Did the patients use their medicine properly?’ Combining this powerful new data with the technology, analysis, and capabilities of Oracle Health Sciences creates a game-changing opportunity for drug development,” said Markus Christen, head of global development, Proteus Digital Health.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.